The FDA has endorsed Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo for adults ages 18 to 59 who are at an increased risk of developing lower respiratory tract disease (LRTD).

The U.S. is entering the second RSV season in which vaccines for the virus are available for older adults. Yet, despite three options on the market from Pfizer, GSK and Moderna, uptake has been slow ...

(NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF ...

New real-world data suggests that seniors who get the RSV vaccine have an 80% lower odds for severe illness It's yet another reason to get immunized ahead of another RSV season Widespread immunization ...

RSV is a significant public health concern for vulnerable populations, especially the elderly and newborns. Researchers estimate that nearly every child will be infected by the age of two. While ...

Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...

was a significant revision of the American Standard Version. It sought to combine modern scholarship with a literary style similar to the KJV. The RSV became widely used in both Protestant and ...